2026-08-05T15:42:55Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/177452024-09-21T20:54:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Merino-Casabiel, X author Aller, J author Arbizu, J author García-Figueiras, R author González, C author Grande, E author Jiménez-Fonseca, P author Sevilla, M I author Capdevila, J 2024-02-09T15:59:28Z 2024-02-09T15:59:28Z 2018-05-15 10.1007/s12094-018-1881-9 1699-3055 Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico http://hdl.handle.net/10668/12473 29766455 http://hdl.handle.net/20.500.12105/17745 Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should differ from other kind of tumors. To answer relevant questions about which techniques are best in the assessment of progression or treatment response a RAND/UCLA-based consensus process was implemented. Relevant clinical questions were listed followed by a systematic search of the literature. The expert panel answered all questions with recommendations, combining available evidence and expert opinion. Recommendations were validated through a questionnaire and a participatory meeting. Expert recommendations regarding imaging tools for tumor assessment and evaluation of progression were agreed upon. Available imaging techniques were reviewed and recommendations for best patient monitoring practice and the best way to evaluate treatment response were formulated. eng Diagnostic imaging Molecular imaging Neuroendocrine tumors Nuclear medicine Radionuclide imaging Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. research article